ASM INTERNATIONAL N.V. ANNOUNCES Q2 2021 ORDERS CLEARLY ABOVE GUIDANCE
Almere, the Netherlands
July 1, 2021, 5:45 p.m. CET
ASM International N.V. (Euronext Amsterdam: ASM) today announces that order intake in the second quarter of 2021 was clearly above previous guidance.
Based on preliminary numbers, order intake in Q2 2021 is expected to slightly exceed €500 million, clearly above the range of €420-440 million that ASMI guided for with the publication of the Q1 2021 results on April 20, 2021.
The upside in the order intake in Q2 is mainly the result of orders that were previously expected in Q3 and that have now been pulled in by customers to Q2.
Revenue in Q2 2021 is expected to be in line with the previous guidance of €390-€410 million. We have not changed our expectations for sales in the second half, which are still expected to be at least at the same level as in the first half.
ASMI will report second quarter 2021 financial results on July 27, 2021.
About ASM International
ASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and participations provide production solutions for wafer processing (Front-end segment) as well as for assembly & packaging and surface mount technology (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI's website at www.asm.com.
Cautionary Note Regarding Forward-Looking Statements: All matters discussed in this press release, except for any historical data, are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These include, but are not limited to, economic conditions and trends in the semiconductor industry generally and the timing of the industry cycles specifically, currency fluctuations, corporate transactions, financing and liquidity matters, the success of restructurings, the timing of significant orders, market acceptance of new products, competitive factors, litigation involving intellectual property, shareholders or other issues, commercial and economic disruption due to natural disasters, terrorist activity, armed conflict or political instability, changes in import/export regulations, epidemics and other risks indicated in the Company's reports and financial statements. The Company assumes no obligation nor intends to update or revise any forward-looking statements to reflect future developments or circumstances.
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
Investor and Media contact:
T: +31 88 100 8500
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Ahold Delhaize share buyback update27.7.2021 08:00:00 CEST | Press release
Zaandam, the Netherlands, July 27, 2021 – Ahold Delhaize has repurchased 253,889 of Ahold Delhaize common shares in the period from July 19, 2021 up to and including July 23, 2021. The shares were repurchased at an average price of € 25.49 per share for a total consideration of € 6.5 million. These repurchases were made as part of the €1 billion share buyback program announced on November 4, 2020. The total number of shares repurchased under this program to date is 22,071,395 common shares for a total consideration of € 512.9 million. Download the share buyback transactions excel sheet for detailed individual transaction information from https://www.aholddelhaize.com/en/investors/share-buyback-programs/2021/ This press release is issued in connection with the disclosure and reporting obligation set out in Article 2(2) of the EU Regulation that contains technical standards for buyback programs.
Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company27.7.2021 07:01:34 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 27, 2021 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2021. Business highlights Daridorexant for the treatment of insomnia under review with US FDA, EMA, and SwissmedicNine scientific presentations for daridorexant shared at SLEEP 2021Ponesimod to treat relapsing forms of multiple sclerosis was approved by the US FDA and the European Commission, Idorsia receives first income from the revenue-sharing agreement in respect to ponesimodClazosentan NDA for the treatment of cerebral vasospasm post aneurysmal subarachnoid hemorrhage (aSAH) submitted to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in March 2021“SOS-AMI” Phase 3 registration study with selatogrel in suspected acute myocardial infarction (AMI) initiated in June 2021Phase 2 study with ACT-539313 for binge eating disorder initiated in March 2021Results for MODIFY Phase 3 study with lucerastat for Fabry
Hyloris to Report 2021 Half-Year Results on 4 August 202127.7.2021 07:00:00 CEST | Press release
Liège, Belgium – 27 July 2021 –Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that it will host a conference call and audio webcast on Wednesday, 4 August 2021 at 3:00 pm CEST (9:00 am EST) to present its half-year 2021 financial results and to provide a business update. The presentation will be followed by a live Q&A session. The webcast may be accessed on the Events page of the company’s website or by clicking here. To participate in the Q&A session of the conference call, please dial one of the following numbers, ten minutes prior to the start of the live webcast: Belgium +32 2 79 338 47 France +33 1 70 700 781 Netherlands + 31 20 795 6614 United Kingdom +44 2071 928 338 United States +1 646 741 3167 Confirmation code 2687826 Following the call, a replay of the webcast will be available on the events page of the Hyloris website. About Hyloris Phar
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor27.7.2021 07:00:00 CEST | Press release
Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation)i; agent is being studied in an area of significant unmet need Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Jersey City, N.J., Geneva, Switzerland, July 27, 2021 - Organon (NYSE: OGN), a global women’s health company and ObsEva (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company dedicated to improving women’s reproductive health, today announced that the companies have entered into an agreement whereby Organon will license the global development, manufacturing and commercial rights to ebopiprant (OBE022). Ebopiprant is an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions. If approved, it has potential to be a first-in-class innovation for this common and serious condition with no approved therapies for acute treatme
Wereldhave N.V.: Results H1 202127.7.2021 07:00:00 CEST | Press release
Key items Major step in phasing out France: sold four out of six French assets for € 305mBenelux disposal program finalized, Koningshoek sold above book value LTV down to 46% - pro-forma for four asset French disposal 42%Dutch valuations stabilizing for the first time in nine valuation roundsAs a result of disposals, outlook 2021 direct result now at € 1.75 - 1.85 per shareOutlook direct result 2022 reiterated at € 1.40 - € 1.50 per share; to be followed by 4 - 6% annual growthDividend guidance 2021 minimum € 1.00 per share Attachment Wereldhave pr 2021-H1 - vFINAL
Leasinvest Real Estate SA: Publication of a transparency notification26.7.2021 18:00:00 CEST | Press release
PUBLICATION OF A TRANSPARENCY NOTIFICATION IN ACCORDANCE WITH THE LAW OF 02/05/2007 ON THE DISCLOSURE OF IMPORTANT PARTICIPATIONS A notification of 26 July 2021 issued by AG Insurance, shows that both a passive threshold overrun and a drop below the minimum threshold took place, following the introduction of the double voting rights and a capital increase by contribution in kind from a/o Extensa Group, as approved at the extraordinary general meeting of Leasinvest Real Estate on 19 July 2021. The total number of voting rights of AG Insurance in Leasinvest Real Estate has therefore decreased to 2.58% of the voting rights in Leasinvest Real Estate NV (hereinafter the "Company”). The notification comprises the following information: REASON FOR THE NOTIFICATION: Passive threshold overrun - Drop below the minimum threshold NOTIFICATION: by the parent company or controlling person. PERSON(S) SUBJECT TO THE NOTIFICATION REQUIREMENT Name and legal formAddress Ageas SA/NV Rue du Marquis 1, 1000
PRESS RELEASE: BIGBEN: Q1 2021/22 Sales26.7.2021 17:50:00 CEST | Press release
Bigben Press release Lesquin, 26 July 2021 18:00 hrs Q1 2021/22 Sales: 56.7 M€ (+2.8%) High sales historyforNacon Gaming Favourable base effect for Audio-Telco Confirmation of FY 2021/22 and FY 2022/23 targets IFRS – M€ Sales 2021/2022 2020/2021 Change 1st Quarter Nacon Gaming Bigben Audio-Telco 56.7 33.7 23.0 55.2 38.0 17.2 +2.8% -11.3% +33.9% Non audited data In Q1 FY 2021/22 (April 1 to June 30, 2021), Bigben posted sales of €56.7 million, an increase of 2.8%, driven by Audio-Telco, which benefited from a favourable comparison basis, unlike the Nacon Gaming business unit, demonstrating the benefit from being present across several markets. NACON GAMING In Q1 2021/22, Nacon achieved sales of 33.7 M€, down 11.3% on Q1 2020/2021. Despite an unfavourable comparison basis, the back catalogue showed a positive momentum. Games: The segment posted sales of 12.2 M€, down 16.0% compared with Q1 2020/21, whose back catalogue sales had been boosted by 340% by lockdown. The back catalogue demons